0000000000337187

AUTHOR

Alba Loras

showing 3 related works from this author

Integrative Metabolomic and Transcriptomic Analysis for the Study of Bladder Cancer

2019

Metabolism reprogramming is considered a hallmark of cancer. The study of bladder cancer (BC) metabolism could be the key to developing new strategies for diagnosis and therapy. This work aimed to identify tissue and urinary metabolic signatures as biomarkers of BC and get further insight into BC tumor biology through the study of gene-metabolite networks and the integration of metabolomics and transcriptomics data. BC and control tissue samples (n = 44) from the same patients were analyzed by High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance and microarrays techniques. Besides, urinary profiling study (n = 35) was performed in the same patients to identify a metabolomic profi…

0301 basic medicineCancer ResearchTaurinecancer biomarkersBiologycancer metabolic reprogramminglcsh:RC254-282ArticleTranscriptome03 medical and health scienceschemistry.chemical_compoundtranscriptomics0302 clinical medicineMetabolomicsmedicinemetabolic pathwaysTumor metabolomeBladder cancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmetabolomicsMetabolic pathway030104 developmental biologyOncologyBiochemistrychemistry030220 oncology & carcinogenesisbladder cancerCancer biomarkersDNA microarraytumor metabolome
researchProduct

Urinary Metabolic Signatures Detect Recurrences in Non-Muscle Invasive Bladder Cancer

2019

Patients with non-muscle invasive bladder cancer (NMIBC) undergo lifelong monitoring based on repeated cystoscopy and urinary cytology due to the high recurrence rate of this tumor. Nevertheless, these techniques have some drawbacks, namely, low accuracy in detection of low-grade tumors, omission of pre-neoplastic lesions and carcinomas in situ (CIS), invasiveness, and high costs. This work aims to identify a urinary metabolomic signature of recurrence by proton Nuclear Magnetic Resonance (1H NMR) spectroscopy for the follow-up of NMIBC patients. To do this, changes in the urinary metabolome before and after transurethral resection (TUR) of tumors are analyzed and a Partial Least Square Dis…

0301 basic medicineCancer Researchmedicine.medical_specialtyUrinary systemmetaboliteUrologylcsh:RC254-282Article03 medical and health sciences0302 clinical medicineMetabolomicsCytologyMetabolomeMedicineUrologiametabolic pathwaysCàncerBladder cancermedicine.diagnostic_testbusiness.industryrecurrence predictionCystoscopymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmetabolomicsnuclear magnetic resonance030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)bladder cancerbiomarkerbusinessNon muscle invasivebiomarker bladder cancer metabolic pathways metabolite metabolomics nuclear magnetic resonance recurrence predictionCancers
researchProduct

Bladder cancer recurrence surveillance by urine metabolomics analysis.

2018

AbstractNon Muscle Invasive Bladder Cancer (NMIBC) is among the most frequent malignant cancers worldwide. NMIBC is treated by transurethral resection of the bladder tumor (TURBT) and intravesical therapies, and has the highest recurrence rate among solid tumors. It requires a lifelong patient monitoring based on repeated cystoscopy and urinary cytology, both having drawbacks that include lack of sensitivity and specificity, invasiveness and care costs. We conducted an investigative clinical study to examine changes in the urinary metabolome of NMBIC patients before and after TURBT, as well during the subsequent surveillance period. Adjusting by prior probability of recurrence per risk, dis…

0301 basic medicineOncologyMalemedicine.medical_specialtyUrinary systemlcsh:MedicineUrineArticlelaw.invention03 medical and health sciences0302 clinical medicineMetabolomicsRandomized controlled triallawCytologyInternal medicinemedicineMetabolomeBiomarkers TumorHumansMetabolomicslcsh:ScienceAgedAged 80 and overMultidisciplinaryBladder cancermedicine.diagnostic_testbusiness.industrylcsh:RCystoscopyMiddle Agedmedicine.disease030104 developmental biologyUrinary Bladder Neoplasms030220 oncology & carcinogenesisMetabolomelcsh:QFemalebusinessScientific reports
researchProduct